poisar

Stocks · News reference

$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

BenzingaAug 24, 2026, 11:45 PMBenzinga Insights

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 19.2%. Currently, Regeneron Pharmaceuticals has a market

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 24, 2026, 11:45 PM
Checked
Aug 24, 2026, 11:45 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolAug 21, 2026, 11:02 AMAndy Gould

    IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?

    The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.

    Read original at the-motley-fool